Adaptive Phage Therapeutics - About the company
Adaptive Phage Therapeutics is an acquired company based in Bethesda (United States), founded in 2016. It operates as a Provider of therapies to treat multi drug resistant infections. Adaptive Phage Therapeutics has raised $108M in funding from investors like Bayer, Amgen and Alexandria. The company has 222 active competitors, including 79 funded and 43 that have exited. Its top competitors include companies like Spero Therapeutics, Locus Biosciences and LimmaTech Biologics.
Company Details
Provider of therapies to treat multi-drug resistant infections. The company works towards this goal through PhageBanking, a large collection of bacteriophages or "phages" (viruses that attack specifically targeted bacteria), and they have also developed a rapid system for matching phages to patient-specific bacterial infections. The company's technology assists in the survival of a multi-drug resistant Acinetobacter baumanii patient, which was part of their FIH success.
- Social
- Email ID
- *****@aphage.com
- Registered Address
- Gaithersburg, Maryland
Key Metrics
Founded Year
2016
Location
Bethesda, United States
Stage
Acquired
Total Funding
$108M in 11 rounds
Latest Funding Round
Ranked
41st among 222 active competitors
Employee Count
10 - 49 as on Mar 01, 2026
Similar Companies
Exit Details
Acquired by BiomX (Mar 06, 2024)
Legal entities associated with Adaptive Phage Therapeutics
Adaptive Phage Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ADAPTIVE PHAGE THERAPEUTICS CIN: 814208730 , United States, Active | Dec 26, 999 | - | 78 (As on Dec 31, 2022) | - |
Adaptive Phage Therapeutics's acquisition details
Adaptive Phage Therapeutics got acquired by BiomX on Mar 06, 2024.
Click here to take a look at Adaptive Phage Therapeutics's acquisition in detail
Sign up to download Adaptive Phage Therapeutics' company profile
Adaptive Phage Therapeutics's funding and investors
Adaptive Phage Therapeutics has raised a total funding of $108M over 11 rounds. Its first funding round was on Apr 13, 2017. Its latest funding round was a Series B round on Jun 09, 2023 for $*****. 2 investors participated in its latest round. Adaptive Phage Therapeutics has 11 institutional investors.
Here is the list of recent funding rounds of Adaptive Phage Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 09, 2023 | 2071414 | Series B | 9369915 | 9088742 | 7127091 | 7153837 |
Apr 04, 2022 | 2165408 | Series B | 4363609 | 3994437 | 8061342 | |
Sep 30, 2021 | 7022668 | Grant (prize money) | 6660001 | 1170464 | 5374917 |
Access funding benchmarks and valuations. Sign up today!View details of Adaptive Phage Therapeutics's funding rounds and investors
Adaptive Phage Therapeutics' founders and board of directors
Founder? Claim ProfileAdaptive Phage Therapeutics' employee count trend
Adaptive Phage Therapeutics has 10 - 49 employees as of Mar 26. Here is Adaptive Phage Therapeutics's employee count trend over the years:
Uncover Adaptive Phage Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Adaptive Phage Therapeutics's Competitors and alternates
Top competitors of Adaptive Phage Therapeutics include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of Adaptive Phage Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Spero Therapeutics 2013, Cambridge (United States), Public | Developer of therapeutics for drug-resistant bacterial infections | $115M | 70/100 | |
2nd | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 64/100 | |
3rd | LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired | Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques | $40M | 63/100 | |
4th | Microbiome therapeutics for diseases associated with microbiome dysbiosis | $56M | 62/100 | ||
5th | MicuRx Pharmaceuticals 2007, Foster City (United States), Series E | Develops antibiotics against multidrug-resistant (MDR) superbug infections | $272M | 61/100 | |
6th | Paratek Pharma 1996, Boston (United States), Acquired | Developer of therapeutics for antimicrobial resistant infections | $96.5M | 61/100 | |
7th |  Everest Medicines 2017, New York City (United States), Public | Developer of drugs for the treatment of cancer | $313M | 61/100 | |
8th |  Bioversys 2008, Basel (Switzerland), Public | Developer of therapeutics for Antimicrobial Resistance | $62.5M | 61/100 | |
9th |  Vedanta Biosciences 2010, Cambridge (United States), Series E | Developer of therapeutics to treat infectious diseases | $410M | 59/100 | |
10th | Developer of multi-targeted antibacterial compounds | $7.51M | 59/100 | ||
41st | Adaptive Phage Therapeutics 2016, Bethesda (United States), Acquired | Provider of therapies to treat multi drug resistant infections | $108M | 46/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Adaptive Phage Therapeutics's competitors? Click here to see the top ones
Adaptive Phage Therapeutics's Investments and acquisitions
Adaptive Phage Therapeutics has made no investments or acquisitions yet.
Reports related to Adaptive Phage Therapeutics
Here is the latest report on Adaptive Phage Therapeutics's sector:
News related to Adaptive Phage Therapeutics
Filter this list•
Haynes Boone Advises BiomX in Completed Merger with Adaptive Phage Therapeutics and $50MM FinancingABL Advisor•Mar 20, 2024•Haynes and Boone, BiomX, Adaptive Phage Therapeutics
•
Telum Therapeutics appoints Dr. Subhendu Basu as CEOPR Newswire•Mar 19, 2024•Telum Therapeutics, Adaptive Phage Therapeutics
•
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million FinancingTMC•Mar 18, 2024•BiomX, Adaptive Phage Therapeutics, phagetx.com
•
Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage TherapeuticsPR Newswire•Mar 07, 2024•Ademi, BiomX, Adaptive Phage Therapeutics
•
BiomX merges with APT, secures $50M for clinical trialsInvesting•Mar 06, 2024•BiomX, Adaptive Phage Therapeutics
•
Gaithersburg biotech initiates another round of layoffs as longtime CEO steps backThe Business Journals•Jan 17, 2024•Adaptive Phage Therapeutics
•
Gaithersburg's Adaptive Phage Therapeutics raising $30M for superbug-killing therapyThe Business Journals•Jun 13, 2023•Adaptive Phage Therapeutics
•
Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical CenterBusiness Wire•May 24, 2023•Adaptive Phage Therapeutics, Hadassah
•
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory InfectionPipelinereview•Jan 13, 2023•Adaptive Phage Therapeutics
•
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory InfectionBusiness Wire•Jan 12, 2023•Adaptive Phage Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Adaptive Phage Therapeutics
Explore our recently published companies
- Axa Ubezpieczenia - Warsaw based, Unfunded company
- NX2 Northern Express - Warkworth based, 2016 founded, Unfunded company
- JAEM.me - Funding Raised company
- Shine Web - 2015 founded, Unfunded company
- What Matters - Amsterdam based, 2011 founded, Unfunded company
- Hassel Michael GmbH Intern. Tierparkversorgung - Germany based, Unfunded company
